INTRODUCTION {#s1}
============

Population-wide studies have shown that chronic lymphocytic leukemia (CLL) shows remarkable geographic and ethnic variations. CLL is the most common leukemia in the United States (\> 30% of all leukemia) and the least common leukemia in India (\< 5% of all leukemia). The epidemiologic estimates of CLL in India are compared with that in the United States in [Table 1](#T1){ref-type="table"}.^[@B1]^ This lower incidence among Asians persists even for migrants and their descendants to the west.^[@B2],[@B3]^ There are data to suggest that the clinical presentation of CLL may be different in the Asian population. This is seen in terms of the younger age of presentation, aggressive course, and shorter time to treatment.^[@B4]^ The exact reasons for the low prevalence of CLL in the Indian population are still unknown, and answers to these may exist in clinical-epidemiologic studies. There is paucity of CLL data from the Indian subcontinent, with scarce data on epidemiology, clinical presentation, and treatment outcomes.^[@B5]^ It is even more relevant in the era when most countries with universal health coverage are moving to chemotherapy-free regimens. Although chlorambucil monotherapy is considered palliative in these countries,^[@B6]^ it is often the only therapy affordable to most patients in the low to middle sociodemographic index (SDI) countries.^[@B7]^ This study sheds light on the demographics, clinical presentation, treatment options, and outcomes in India.

CONTEXT
-------

**Key Objective**In this prospective study, we report what is, to the best of our knowledge, the largest data set of chronic lymphocytic leukemia (CLL) from the Indian subcontinent.**Knowledge Generated**Indian patients with CLL are younger in chronological age but have higher morbidity burden. Treatment outcomes with biosimilar fixed-dose rituximab + bendamustine are comparable to those reported in the literature. Chlorambucil is still a valid option in regions with limited resources.**Relevance**These CLL data from a resource-limited setting highlight the differences in demographics and clinical presentation but show that treatment outcomes using the options available are comparable to the clinical trial and real-world data from regions without resource limitations.
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Epidemiologic Estimates of Chronic Lymphocytic Leukemia in India and the United States^[@B1]^
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METHODS {#s2}
=======

This was a prospective single-center study conducted from 2011-2017 at a large academic institute in North India. This study was approved by the institutional ethics committee. All consecutively diagnosed patients with CLL registered in the adult hematology clinic were enrolled in the study after informed consent. The diagnosis of CLL required ≥ 5 × 10^9^/L clonal B lymphocytes in peripheral blood and was confirmed on multiparameter flow cytometry as per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines.^[@B8]^ Patent demographics, clinical presentation, clinical stage, prognostic parameters (β~2~ microglobulin \[β2m\], lymphocyte doubling time \[LDT\], CD38 status, and fluorescence in situ hybridization \[FISH\] test) were recorded at diagnosis. Asymptomatic patients were kept on observation. Treatment was initiated as per the iwCLL criteria. The choice of treatment was at the discretion of the treating physician in consultation with the patient as per his/her financial and supportive care status. In general, fit patients with financial resources were offered bendamustine-rituximab (BR), unfit patients with financial resources were offered rituximab-chlorambucil (R-Clb), and patients without financial resources were offered chlorambucil ± prednisolone (Clb ± P)--based therapies. Biosimilar rituximab was dosed at 375 mg/m^2^ for all cycles 1-6, rather than escalating to 500 mg/m^2^ from cycle 2-6. Bendamustine was dosed at 90 mg/m^2^ on days 1 and 2 in a 28-day cycle. Chlorambucil dosing was 10 mg/m^2^ with/without prednisolone 60 mg/m^2^ for 5 days in a 28-day cycle. Fludarabine-cyclophosphamide-rituximab (FCR) was offered to very few fit patients with financial resources and good supportive care, and ibrutinib was beginning to be offered in patients with deletion 17p and financial resources toward the end of the study period. Patients with autoimmune cytopenias were treated with single-agent immunosuppressive therapy with prednisolone or rituximab. No routine anti-infective prophylaxis was given with any treatment. Vaccination, granulocyte colony-stimulating factor, and immunoglobulin use were at the discretion of the treating physician and as clinically indicated. Patients were followed up to monitor cytopenias as per iwCLL criteria^[@B8]^ and infections as per Common Terminology Criteria for Adverse Events version 4.0 criteria. The response was assessed at 2 months after completion of the treatment as per iwCLL criteria.^[@B8]^ This was mainly done clinically, with minimal investigations of hemogram, chest radiograph, and abdomen ultrasound. Computed tomography (CT) imaging and bone marrow examination were not done in all patients. Hence, responses were documented as unconfirmed complete response (CRu). Time to next treatment (TTNT) was defined as the time from front-line treatment initiation to next treatment or death from any cause. TTNT2 was defined as the time from second-line treatment initiation to subsequent next treatment or death from any cause. Progression-free survival (PFS) could not be calculated in most patients because of the lack of availability of absolute lymphocyte counts on each follow-up visit after treatment. Overall survival (OS) was defined as the time from treatment initiation until death from any cause.

Statistical Analysis {#s3}
--------------------

Descriptive statistics were calculated for all variables. Differences in proportions were assessed using the χ^2^ or Fisher exact test. Differences in means were tested using a Mann-Whitney *U* test or *t* test. The probability of survival was estimated using Kaplan-Meier analysis and log-rank test. A *P* value ≤ .05 was taken for statistical significance. Statistical analysis was performed with SPSS statistical software version 20.0 (SPSS, Chicago, IL).

RESULTS {#s4}
=======

Clinical Presentation of CLL {#s5}
----------------------------

A total of 409 patients diagnosed with CLL were enrolled in the study period. The median follow-up was 32 months (range, 2-135 months). The median age of the patients with CLL at diagnosis was 61 years (range, 31-87 years). There was male preponderance, with male-to-female ratio of 2.4:1. The prevalence of young CLL (age ≤ 55 years) was 31.8% of the total study population. Our center is a tertiary-level referral center in north India; the majority of patients were from Punjab (42.8%), followed by Haryana (24.4%), Chandigarh (11%), and Himachal Pradesh (9.5%). The remainder of the patients (12.3%) belonged to the states of Uttar-Pradesh, Jammu and Kashmir, Uttarakhand, West-Bengal, Bihar, Gujarat, and Rajasthan. Most of the patients were in office jobs (28.1%), followed by homemakers (23.7%) and farmers (19.5%); the rest were either retired or in other occupations (23.7%). Approximately half (47.9%) of the patients were of low socioeconomic status. The majority (42.3%) of the patients were asymptomatic (incidentally detected lymphocytosis) at presentation; 28.6% patients were aware of lymphadenopathy at presentation. The rest of the patients (14.9%) presented with pneumonia or other infections. B symptoms were present in 14.2% of the patients. Two patients had concurrent diffuse large B-cell lymphoma at diagnosis. A quarter (24.7%) of the patients had an Eastern Cooperative Oncology Group performance status of 2-4. The cumulative illness rating scale (CIRS), which is a measure of the comorbidity burden, was ≥ 3 in 43.3% of patients. There was an even distribution of patients with CLL as per Rai stage, with 20%, 25.4%, 20.8%, and 21.8% belonging to Rai stage I, II, III, and IV, respectively. Relatively fewer patients presented with Rai stage 0 (12%). All the prognostic information was not available in all patients. Approximately 40% of patients had worse prognostic markers in the form of increased β2m, LDT \< 6 months, or a positive CD38 by flow. FISH data were available in 53.3% of patients. Deletion 17p and 11q were present in 10.5% and 9.2% of patients, respectively. Immunoglobulin heavy chain gene (IgHV) mutation status was unavailable. The demographic and clinical characteristics of the patients are summarized in [Table 2](#T2){ref-type="table"}.
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Demographic and Clinical Characteristics of Patients With Chronic Lymphocytic Leukemia at Diagnosis (N = 409)
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Treatment Outcomes {#s6}
------------------

A total of 70 patients (17.1%) were lost to follow-up after registration. Of the rest, 199/339 (58.7%) patients required treatment as per iwCLL criteria, and 140 (41.3%) patients remained on observation. Out of these, 19 patients were treated for autoimmune cytopenias, and the remaining 180 patients were treated with chemoimmunotherapy for CLL. Most patients in our center received Clb ± P (52.2%)--based treatment. BR was the second most common regimen (31.6%). Other patients received FCR (3.3%), R-Clb (3.8%), CVP/CHOP (rituximab, cyclophosphamide, vincristine, prednisolone, hydroxydaunorubicin, oncovin; 4.4%), ibrutinib (n = 4), R-CHOP (n = 3), or R plus high-dose methylprednisolone (n = 1). A total of 77.2% of the patients attained CRu with BR therapy. Most patients attained partial response (71.3%) with Clb-based therapy. Severe (grade 3-4) neutropenia and consequently severe infections were seen in 52.6% and 38.5% of patients in the BR arm. Chlorambucil was well tolerated, with a lesser incidence of severe cytopenias and infections. The median TTNT was significantly different between BR and Clb ± P (not reached *v* 33 months; *P* = .001; [Fig 1](#f1){ref-type="fig"}). The TTNT was not reached for FCR and R-Clb treatments as well in small patient numbers. The median OS was not reached in both BR and Clb ± P groups (*P* = .25; [Fig 2](#f2){ref-type="fig"}; [Table 3](#T3){ref-type="table"}). Only 1 patient developed Richter's transformation after front-line BR and went on to receive matched sibling allogeneic transplantation after 2 more lines of therapy.

![Time to next treatment (TTNT) after first-line therapy. BR, bendamustine + rituximab; Clb, chlorambucil; P, prednisolone.](GO.20.00032f1){#f1}

![Overall survival (OS) after first-line therapy. BR, bendamustine + rituximab; Clb, chlorambucil; P, prednisolone.](GO.20.00032f2){#f2}
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Treatment Outcomes and Toxicity With Front-Line Clb and BR
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A total of 64 (35.5%) patients relapsed after first-line therapy. The most common second-line treatment options were BR (n = 17), Clb ± P (n = 13), and R-Clb (n = 12). Other treatment regimens included CVP (n = 7), CHOP/R-CHOP (n = 6), and ibrutinib (n = 3), and 1 patient each received FCR, lenalidomide, R-CVP, R-DHAP (dexamethasone, high-dose cytarabine, cisplatin), R-ESHAP (etoposide, methylprednisolone, high-dose cytarabine, cisplatin), or R-lenalidomide. These heterogeneous treatment regimens were not included for statistical analysis because of small patient numbers. The overall response rate (ORR) with BR and R-Clb--based therapy was similar at 87.5% and 88.8%, respectively. The incidence of grade 3/4 neutropenia was higher in the relapsed setting after BR (64.7%) compared with the front-line setting. The chlorambucil arm was still effective in achieving overall response at first relapse (76.9%). The TTNT2 was not statistically different between BR (42 months), R-Clb (not reached), and Clb groups (30 months; *P* = .2).

DISCUSSION {#s7}
==========

This the largest real-world data set of CLL from India, to the best of our knowledge. The sex ratio is comparable to that reported in the literature. Our study has a higher proportion of younger (age ≤ 55 years) patients with CLL (31.8%) compared with other studies in the West (10%).^[@B9]^ The median age is also a decade earlier in Indian patients (61 years) compared with those reported in the literature from high-SDI countries (70 years).^[@B9]^ This could be due to a referral bias but has been observed for other hematologic malignancies from India as well.^[@B10],[@B11]^ This assumes significance, given younger patients with CLL are likely to have worse prognostic factors and inferior OS compared with age- and sex-matched populations.^[@B12]^ More patients in our study presented with inferior health status as determined by CIRS ≥ 3 (43.3% *v* 11%) compared with the patients from high-SDI countries.^[@B13]^ This might be due to the late presentation to the clinic or poor fitness profile of Indian patients.^[@B14]^

Although Rai staging was available in all patients, basic prognostic laboratory information, including β2m, LDT, or CD38, was not available in a quarter of the patients. FISH data were available in 53.3% of patients, which is higher than would be available for other centers even in high-SDI countries^[@B15]^ (49.9%), because they were obtained as a part of a research project in this academic center. IgHV mutation testing is still not routine at our center, although this test is available at a few private laboratories and research centers.^[@B16]^

The overall response rates with BR were comparable to the outcomes reported from clinical trial^[@B17]^ and real-world data from Germany^[@B18]^ ([Table 4](#T4){ref-type="table"}). We had a higher unconfirmed CR rate compared with CR rates in clinical trials, as most patients did not get end-of-treatment CT imaging and bone marrow examination, which are desirable in clinical trials for documenting outcomes. The median TTNT was better documented in the patients than the PFS. Most patients did not have absolute lymphocyte counts on follow-up to document disease progression to calculate PFS. Also, TTNT is a better surrogate of treatment outcomes than PFS, as patients with CLL are treated only when symptomatic after relapse. The TTNT in our BR cohort was not reached, as compared with the PFS from trial data (42 months) and real-world data (30.6 months). The adverse event profile was comparable across the studies, except for higher rate of infections in our study group. Some differences in the frequency of cytopenias reported might be due to the different criteria used (National Cancer Institute Common Toxicity Criteria used in other studies *v* the iwCLL criteria used in our study). BR was still an effective treatment at first relapse, with a TTNT2 of 42 months ,compared with 31.3 months reported from a real-world European study.^[@B19]^
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Comparison of the Treatment Outcomes of BR With Clinical Trial and Real-World Data
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In today's world, there is little role for chlorambucil monotherapy in high-SDI countries.^[@B20]^ Consequently, there are no recent real-world data on the same from these countries. However, this represents a major therapeutic option even to date in India, given the outpatient administration and meager costs, specifically in patients of low socioeconomic strata, which were half our study population. The outcomes with chlorambucil therapy, when compared with trials,^[@B18],[@B19]^ showed a comparable response rate and a longer TTNT ([Table 5](#T5){ref-type="table"}). The adverse event profile was comparable and manageable compared with patients in the BR cohort. The median TTNT2 after Clb-based retreatments was still significant, as with first-line treatment, specifically when used in combination with rituximab. Retreatment at first relapse with the same agents used front line (BR- or Clb-based treatments) is still effective in a subset of patients who have a TTNT \> 24 months after initial therapy.
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Comparison of the Treatment Outcomes of Clb ±P With Clinical Trial Data
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The per capita gross national income in India is approximately \$2,000.^[@B21],[@B22]^ Only a quarter of the population in India had some form of medical coverage until the year 2017.^[@B23]^ The cost of rituximab-based regimens is upward of \$2,000 for 6 cycles ([Table 6](#T6){ref-type="table"}). This is why there was less use of rituximab-based regimens in our patients. However, with the launch of the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) in 2018, which aims to publicly provide insurance coverage of \$7,000 per family per year for up to 500 million people,^[@B24]^ the utilization rates of rituximab-based regimens are already up. A total of 45/80 (56.2%) patients have so far received rituximab-based regimens in the year 2018-2019 at our center.
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Direct Costs for Diagnosis, Investigations, and Treatment of Chronic Lymphocytic Leukemia in India and United States
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The outcomes of patients lost to follow-up are unknown. Prognostic information is unavailable for the majority of the patents. Data on dose and cycle adjustments were not documented in all patients. The CR was unconfirmed in the absence of a bone marrow examination. Minimal residual disease data were unavailable in this cohort of patients. TTNT rather than PFS data were available. A longer follow-up is required to study the overall survival outcomes. The data from this single-center study may not be entirely reflective of the practices or outcomes in all centers, given the heterogeneity in patients and the health care delivery systems, but they are likely representative of data from most tertiary referral centers in India.^[@B25]^
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